Summary by Futu AI
EyePoint Pharmaceuticals, Inc. (EYPT) has filed a Form 3 with the SEC, indicating a significant change in ownership by key insiders. The filing, dated April 18, 2024, reveals that Adage Capital Management, L.P. now beneficially owns 5,156,299 shares of EyePoint Pharmaceuticals' common stock indirectly, marking them as a 10% owner. The filing also lists Robert Atchinson and Phillip Gross, managing members of related entities to Adage Capital Management, as reporting persons. Both Atchinson and Gross have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest. The filing was completed and signed on April 22, 2024, by Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross.